STOCK TITAN

Immatics N.V. (IMTX) SEC Filings

IMTX NASDAQ

Immatics N.V. filings document a foreign private issuer whose regulatory record centers on clinical-stage oncology development, financing capacity and public-company governance. Form 6-K reports furnish press releases, interim reports and investor presentations covering PRAME cell therapy and TCR bispecific programs, including anzu-cel, IMA203CD8, IMA402 and IMA401 MAGEA4/8, along with financial results and business updates.

The filings also include incorporation-by-reference language for Form S-8 and Form F-3 registration statements, leadership and governance disclosures, forward-looking clinical and regulatory risk statements, and capital-structure or shareholder matters tied to the company's Nasdaq-traded security.

Rhea-AI Summary

Immatics N.V. Chief Business Officer Rainer Kramer exercised options for 22,868 ordinary shares at $1.06 per share on November 19, 2026, then sold 22,868 shares at a $6.06 weighted average price in multiple transactions priced from $6.03 to $6.12. The reported option position after exercise was zero. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Immatics N.V. (IMTX) officer Rainer Kramer gave notice of a planned sale of 22,868 common shares, with an approximate sale date of November 19, 2026, and an aggregate market value of $138,586.94. The notice lists the same 22,868 shares as acquired from the issuer through a stock option exercise, with cash payment, on November 19, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
other
-
Rhea-AI Summary

For Immatics N.V. (IMTX), Vestal Point Capital, LP and Ryan Wilder, Vestal Point Capital’s Chief Investment Officer and Managing Partner, reported beneficial ownership of 15,515,304 ordinary shares, or 9.9%, with shared voting and dispositive power. The amount includes 4,315,304 ordinary shares issuable upon exercise of pre-funded warrants. The interests relate to shares and warrants directly held by the Vestal Point Fund and Account; both reporting persons listed zero sole voting and dispositive power. The percentage calculation uses 152,225,077 ordinary shares outstanding after the offering and assumes exercise of the warrants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
ownership
Rhea-AI Summary

Immatics N.V. (IMTX) is the issuer in an amended beneficial-ownership disclosure by Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker and Felix J. Baker. Each reporting person lists the same 4,256,682 ordinary shares, or 2.8%; the shares are directly held by Baker Brothers Life Sciences, L.P. and 667, L.P., and are reported as beneficially owned by the reporting persons.

The reporting persons report sole voting and dispositive power over the shares. The ownership percentage is based on 152,266,773 ordinary shares outstanding as of September 30, 2026. The management agreements give the Adviser discretion and authority over the funds’ investment and voting power.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
ownership
-
Rhea-AI Summary

Immatics N.V. (IMTX) is the subject of a Schedule 13G amendment in which T. Rowe Price Investment Management, Inc. reports 25,149,155 common shares, or 17.1% of the class, as beneficially owned. It lists sole voting power over 25,109,257 shares and sole dispositive power over 25,149,155 shares, with shared voting and dispositive power of zero. T. Rowe Price Investment Management states that the report is not an admission of beneficial ownership and expressly denies being the beneficial owner.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.44%
Tags
ownership
-
Rhea-AI Summary

Immatics N.V. (IMTX) is the issuer whose ordinary shares Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen reported as beneficially owned. Montanova Capital and Cowen each reported 8,750,816 shares, or 5.8%, with shared voting and dispositive power. Averill Master Fund reported 7,464,908 shares, or 4.99%, also with shared voting and dispositive power.

The reported shares are directly owned by Montanova Capital’s advisory clients, and none of those clients may be deemed to beneficially own more than 5%. Each reporting person disclaims beneficial ownership except to the extent of its or his pecuniary interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.44%
Tags
ownership
Rhea-AI Summary

Immatics N.V. reported third-quarter and nine-month 2026 results for periods ended September 30. Collaboration revenue for the quarter was €6.9 million, compared with €5.2 million a year earlier, while nine-month revenue was €23.7 million versus €28.5 million. Net loss was €76.0 million for the quarter and €196.3 million for nine months, compared with €50.5 million and €160.7 million in 2025. Research and development expenses were €70.3 million for the quarter and €191.9 million for nine months.

Cash and cash equivalents were €276.6 million and other financial assets were €195.7 million as of September 30, 2026. Management believes these resources are sufficient to fund operating expenses and capital expenditure requirements through at least the next 12 months. Nine-month operating cash outflow was €163.2 million, versus €118.0 million in 2025. On August 26, 2026, the company closed an offering of 15,535,100 ordinary shares and issued 4,315,304 pre-funded warrants; gross proceeds were €115.7 million from shares and €32.1 million from warrants.

The Phase 3 SUPRAME trial is ongoing, with required randomizations on track to be completed by year-end. Immatics expects topline data from the final progression-free survival analysis in the first half of 2027, followed by a BLA submission in 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
current report
-
Rhea-AI Summary

Immatics N.V. (IMTX) reported preliminary updates on its PRAME-directed IMA402 bispecific and IMA203CD8 cell therapy, plus exploratory anzu-cel melanoma analyses. At the June 1, 2026 cutoff, IMA402’s Phase 1b efficacy group included 40 patients in the 10–45 mg recommended Phase 2 dose range; 10 confirmed responses yielded a confirmed objective response rate (cORR) of 25% and a disease control rate of 63% (25/40). Among 31 PRAME-high patients, cORR was 32% (10/31); among 22 PRAME-high melanoma patients, it was 32% (7/22), with median response duration of 12.5 months and median follow-up of 16.8 months. The longest ongoing IMA402 response exceeded 2 years.

Among 126 IMA402-treated patients, no ICANS cases or IMA402-related Grade 5 events were reported. Across IMA203CD8’s evaluated doses, including lower doses not selected for further clinical development, one-time treatment yielded an objective response rate (ORR) of 51% (46/90), cORR of 41% (36/87), and disease control rate of 82% (74/90). An exploratory anzu-cel analysis in 33 melanoma patients reported median progression-free survival (PFS) of 6.1 months; no individually evaluated clinical variable showed a statistically significant association with PFS. First lung-cancer data for IMA402 plus IMA401 are expected in 2027; a Phase 1/2 IMA203CD8 trial in PRAME-positive pediatric cancers is planned to start in 1H 2027. The clinical findings are preliminary and subject to further quality checks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
current report
-
Rhea-AI Summary

Immatics N.V. reported updated Phase 1 data for its investigational IMA203CD8 PRAME-directed TCR T-cell therapy across multiple advanced solid tumor types, using an August 7, 2026 data cutoff. The study included 98 patients in the safety population and 90 efficacy-evaluable patients. Across the evaluable group, the objective response rate was 51% (46/90), confirmed objective response rate was 41% (36/87), disease control rate was 82% (74/90), and tumor reduction was reported in 83% (71/86).

Among 20 patients with gynecologic cancers treated at clinically relevant doses (≥DL4c), ORR was 60% (12/20), confirmed ORR was 55% (11/20), and DCR was 70% (14/20). Median duration of response was 8.4 months with median follow-up of 6.0 months; median progression-free survival was 5.8 months with 8.1 months median follow-up, while median overall survival was not reached at 7.8 months median follow-up. No IMA203CD8-related Grade 5 events were reported, and the maximum tolerated dose was not reached at doses up to 12.5 billion cells.

Phase 1a dose escalation is complete, and enrollment continues for uterine cancer at clinically relevant doses. The company described the clinical data as preliminary and subject to further quality checks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.05%
Tags
current report
Rhea-AI Summary

Immatics N.V. (IMTX) reported an insider Form 4 transaction related to Perceptive entities. On 2026-08-26, Perceptive Life Sciences Master Fund Ltd. purchased 863,060 Ordinary Shares of Immatics at $8.69 per share in an open-market or private transaction. After this purchase, the Master Fund's reported indirect holdings associated with the filing stood at 11,246,516 Ordinary Shares. The shares are directly held by the Master Fund, while Perceptive Advisors LLC serves as investment manager and Joseph Edelman is the managing member of the Advisor; both Edelman and the Advisor disclaim beneficial ownership except to the extent of any indirect pecuniary interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
insider

FAQ

How many Immatics N.V. (IMTX) SEC filings are available on StockTitan?

StockTitan tracks 71 SEC filings for Immatics N.V. (IMTX), including 20-F annual reports and 6-K reports. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Immatics N.V. (IMTX)?

The most recent SEC filing for Immatics N.V. (IMTX) was filed on November 20, 2026.